Stoke Therapeutics (STOK) Competitors $9.76 +0.25 (+2.63%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$9.66 -0.10 (-1.02%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STOK vs. MIRM, BHC, BEAM, GMTX, NAMS, VCEL, BLTE, TARS, JANX, and SDGRShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Mirum Pharmaceuticals (MIRM), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Gemini Therapeutics (GMTX), NewAmsterdam Pharma (NAMS), Vericel (VCEL), Belite Bio (BLTE), Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Mirum Pharmaceuticals Bausch Health Companies Beam Therapeutics Gemini Therapeutics NewAmsterdam Pharma Vericel Belite Bio Tarsus Pharmaceuticals Janux Therapeutics Schrödinger Mirum Pharmaceuticals (NASDAQ:MIRM) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Which has higher valuation and earnings, MIRM or STOK? Stoke Therapeutics has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M6.38-$163.41M-$1.85-23.49Stoke Therapeutics$36.56M14.58-$104.70M-$1.68-5.81 Which has more risk and volatility, MIRM or STOK? Mirum Pharmaceuticals has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Stoke Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Does the media prefer MIRM or STOK? In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Stoke Therapeutics. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 4 mentions for Stoke Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 1.45 beat Stoke Therapeutics' score of 1.05 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MIRM or STOK more profitable? Mirum Pharmaceuticals has a net margin of -31.69% compared to Stoke Therapeutics' net margin of -629.90%. Mirum Pharmaceuticals' return on equity of -41.22% beat Stoke Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-31.69% -41.22% -14.81% Stoke Therapeutics -629.90%-54.45%-40.77% Does the MarketBeat Community favor MIRM or STOK? Mirum Pharmaceuticals received 13 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 76.28% of users gave Stoke Therapeutics an outperform vote while only 75.86% of users gave Mirum Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% Stoke TherapeuticsOutperform Votes11976.28% Underperform Votes3723.72% Do analysts recommend MIRM or STOK? Mirum Pharmaceuticals currently has a consensus target price of $58.20, indicating a potential upside of 33.95%. Stoke Therapeutics has a consensus target price of $24.67, indicating a potential upside of 152.73%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryMirum Pharmaceuticals and Stoke Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$532.87M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-4.657.4422.5718.48Price / Sales14.58242.70395.64103.60Price / CashN/A65.8538.1834.62Price / Book2.736.516.774.25Net Income-$104.70M$143.21M$3.22B$248.23M7 Day Performance-1.21%1.97%1.46%0.89%1 Month Performance56.66%6.89%3.98%3.53%1 Year Performance-15.57%-2.52%16.14%5.09% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics3.5179 of 5 stars$9.76+2.6%$24.67+152.7%-11.5%$532.87M$36.56M-4.65100Upcoming EarningsNews CoverageMIRMMirum Pharmaceuticals4.2437 of 5 stars$41.31+1.3%$58.20+40.9%+73.0%$2.04B$336.89M-20.45140Upcoming EarningsNews CoveragePositive NewsBHCBausch Health Companies4.1743 of 5 stars$5.41-0.6%$7.17+32.5%-39.7%$2.00B$9.63B-45.0819,900Analyst UpgradeNews CoverageGap DownBEAMBeam Therapeutics3.0263 of 5 stars$19.80+1.4%$49.45+149.8%-6.1%$1.99B$63.52M-11.25510Upcoming EarningsShort Interest ↑GMTXGemini TherapeuticsN/A$45.42-1.6%N/A+66.7%$1.97BN/A-45.4230NAMSNewAmsterdam Pharma3.1884 of 5 stars$17.83+1.8%$43.33+143.0%-12.3%$1.96B$45.56M-6.864Positive NewsVCELVericel2.3127 of 5 stars$38.74-2.5%$60.86+57.1%-17.1%$1.94B$237.22M645.77300Upcoming EarningsNews CoveragePositive NewsBLTEBelite Bio2.8216 of 5 stars$60.18+3.3%$96.67+60.6%+51.4%$1.92BN/A-54.2210News CoveragePositive NewsTARSTarsus Pharmaceuticals1.3696 of 5 stars$49.72-0.6%$63.67+28.1%+65.2%$1.91B$182.95M-13.0550Upcoming EarningsPositive NewsJANXJanux Therapeutics3.018 of 5 stars$32.23+3.8%$95.25+195.5%-41.8%$1.90B$10.59M-27.5530Upcoming EarningsNews CoveragePositive NewsSDGRSchrödinger2.2801 of 5 stars$25.75-2.6%$33.00+28.2%+5.1%$1.88B$207.54M-11.00790Upcoming EarningsGap Down Related Companies and Tools Related Companies MIRM Alternatives BHC Alternatives BEAM Alternatives GMTX Alternatives NAMS Alternatives VCEL Alternatives BLTE Alternatives TARS Alternatives JANX Alternatives SDGR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STOK) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy STOK Stock Free STOK Stock Alerts